The global Neurotech Devices Market was valued at USD 14.5 billion in 2024 and is projected to reach USD 32.9 billion by 2032, growing at a CAGR of 10.8% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2024
Forecast Period
2025-2032
Neurotech Devices Market Size 2024
USD 14.5 Billion
Neurotech Devices Market, CAGR
10.8%
Neurotech Devices Market Size 2032
USD 32.9 Billion
The Neurotech Devices Market grows rapidly, driven by the rising prevalence of neurological disorders, increasing demand for minimally invasive treatments, and strong technological advancements in brain-computer interfaces, neurostimulation, and neuroprosthetics. Healthcare providers adopt these devices to improve patient outcomes.
The Neurotech Devices Market demonstrates strong geographical diversity, with North America leading growth due to advanced healthcare infrastructure, high investment in research, and rapid adoption of innovative neurological solutions. Europe follows closely, supported by robust healthcare systems, favorable regulatory frameworks, and rising demand for advanced treatments of neurological disorders. Asia Pacific shows the fastest growth momentum, driven by expanding healthcare infrastructure, large patient populations, and increasing government support for digital health and medical technology. Latin America and the Middle East & Africa also witness steady adoption, supported by growing healthcare modernization efforts. Key players shaping the competitive landscape include Medtronic plc, a leader in neuromodulation and implantable devices; Boston Scientific Corporation, known for innovative neurostimulation solutions; Cochlear Limited, a pioneer in hearing implants; and Nihon Kohden Corporation, recognized for its advanced neurodiagnostic and monitoring technologies. These companies drive innovation, expand applications, and strengthen global adoption of neurotech devices.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Neurotech Devices Market was valued at USD 14.5 billion in 2024 and is projected to reach USD 32.9 billion by 2032, growing at a CAGR of 10.8% during the forecast period.
Rising prevalence of neurological disorders including epilepsy, Parkinson’s disease, Alzheimer’s disease, and chronic pain drives consistent demand for advanced neurostimulation, neuroprosthetic, and brain-computer interface solutions.
Strong technological advancements, including integration of artificial intelligence, wearable devices, and data-driven monitoring, shape the industry’s evolution and enhance adoption across clinical and non-clinical applications.
The competitive landscape features leading players such as Medtronic plc, Boston Scientific Corporation, Cochlear Limited, and Nihon Kohden Corporation, alongside emerging innovators like BrainCo, Control Bionics, and Blackrock Microsystems.
High device costs, limited reimbursement policies, and complex regulatory approval processes remain key restraints, slowing adoption in cost-sensitive and emerging markets.
North America leads adoption with advanced healthcare infrastructure and strong research support, while Europe shows steady growth with favorable regulations; Asia Pacific records the fastest growth, supported by expanding healthcare investments; Latin America and the Middle East & Africa gradually expand adoption through modernization efforts.
The market outlook remains positive with opportunities in mental health, cognitive enhancement, rehabilitation, and digital health integration, supported by growing collaborations between industry leaders, research institutions, and healthcare providers.
Market Drivers
Rising Prevalence of Neurological Disorders Driving Demand for Advanced Devices
The Neurotech Devices Market benefits from the growing incidence of neurological conditions such as epilepsy, Parkinson’s disease, Alzheimer’s disease, and chronic pain disorders. Healthcare systems face increasing pressure to adopt innovative technologies that improve patient outcomes and reduce long-term treatment costs. Governments and health organizations emphasize early diagnosis and effective management, creating consistent demand for advanced neurotech solutions. Patients seek minimally invasive options that enhance quality of life, which strengthens the adoption of neurostimulation and neuroprosthetics. The rising awareness about neurological health expands the patient pool for these devices. This sustained demand provides a strong foundation for market growth.
For instance, Medtronic’s Percept™ PC Deep Brain Stimulation system was launched in 2020 and uses BrainSense™ technology to offer personalized therapy by recording and tracking brain signals. It is used to treat Parkinson’s and other movement disorders, and is available in many countries where it has regulatory approval. While Medtronic has stated that over 185,000 of its DBS devices have been implanted worldwide since 1987, the company has not released a specific patient count for the Percept™ PC system.
Technological Innovations Enhancing Effectiveness and Adoption
The Neurotech Devices Market grows significantly due to rapid advancements in brain-computer interfaces, neuromodulation technologies, and implantable devices. Companies invest heavily in research to create smarter, smaller, and more efficient products with improved safety profiles. It supports the development of devices that integrate with AI and data analytics, enabling precise monitoring and real-time adjustments. Hospitals and clinics adopt these solutions to deliver more personalized treatments. Patients benefit from enhanced recovery rates, encouraging greater acceptance of advanced technologies. This consistent pipeline of innovations ensures a dynamic and competitive market landscape.
For instance, Blackrock Neurotech (formerly Blackrock Microsystems) developed the NeuroPort Array, which often features a configuration of 96 microelectrodes. The NeuroPort system is capable of recording neural activity at a sampling frequency of up to 30 kHz per channel and has been used in dozens of brain-computer interface clinical trials and research studies worldwide.
Expanding Applications Across Healthcare and Beyond Supporting Market Growth
The Neurotech Devices Market extends its applications beyond traditional clinical use, strengthening its role in rehabilitation, mental health management, and assistive care. Hospitals deploy neurostimulation devices for pain management, while rehabilitation centers rely on neuroprosthetics for mobility restoration. It plays a vital role in managing mental health disorders, with emerging devices targeting depression and anxiety. Defense and research institutions explore neurotech for cognitive enhancement and training purposes. These diverse applications broaden the relevance of neurotech across multiple sectors. Such versatility fuels consistent expansion of market opportunities.
Market Trends
Integration of Artificial Intelligence and Data Analytics Transforming Device Capabilities
The Neurotech Devices Market experiences a strong trend toward AI-driven solutions that enhance device performance and treatment precision. AI-powered algorithms help clinicians interpret brain signals, improving diagnosis and therapy outcomes. It enables predictive analytics for early intervention in neurological conditions. Data-driven insights support customized treatment plans, improving patient adherence and satisfaction. Healthcare providers gain real-time monitoring capabilities that enhance efficiency in clinical settings. This integration of advanced analytics strengthens both clinical outcomes and market adoption.
For instance, Nihon Kohden produces the EEG-1200 system: The EEG-1200 is part of the Neurofax line of electroencephalography (EEG) systems from Nihon Kohden, a major medical equipment manufacturer.
Shift Toward Minimally Invasive and Wearable Neurotech Devices
The Neurotech Devices Market advances with growing demand for less invasive solutions that provide comfort and ease of use. Manufacturers focus on compact, wearable devices that patients can use at home with minimal supervision. It reduces hospital visits while promoting continuous monitoring and faster recovery. Lightweight neurostimulation and wearable brain-computer interfaces expand the possibilities for outpatient care. Patient preference for convenient options drives strong interest in this category. This trend improves accessibility while reinforcing long-term treatment adherence.
For instance, Control Bionics developed the NeuroNode Trilogy, a wearable EMG-based device that can detect even the slightest muscle signals, enabling patients with severe paralysis to control computers and communication devices independently.
Expansion of Neurotech Applications in Mental Health and Cognitive Enhancement
The Neurotech Devices Market evolves through increasing adoption of devices targeting mental health conditions such as depression, anxiety, and post-traumatic stress disorder. Clinicians incorporate neuromodulation therapies as effective alternatives to pharmaceuticals. It also explores applications in cognitive enhancement, supporting learning, memory, and focus. Educational and occupational environments begin to recognize the potential of neurotech for performance improvement. Broader acceptance of mental health treatments strengthens the credibility of these devices in mainstream healthcare. This expansion enhances both clinical value and societal impact.
Growing Collaborations Between Industry Leaders and Research Institutions
The Neurotech Devices Market shows a clear trend of collaboration between medical device companies, research centers, and academic institutions. Strategic partnerships accelerate innovation and shorten product development cycles. It encourages the sharing of expertise, funding, and clinical data to improve outcomes. Collaborative research projects foster advancements in neuroprosthetics, brain-computer interfaces, and neuromodulation. These alliances increase the speed of regulatory approvals and support global market entry. This trend creates a robust ecosystem that sustains long-term industry growth.
Market Challenges Analysis
High Costs and Limited Accessibility Restricting Wider Adoption
The Neurotech Devices Market faces significant challenges due to the high cost of advanced devices and limited accessibility across emerging economies. Complex technologies such as brain-computer interfaces and implantable neuromodulation systems require substantial investment in development, manufacturing, and clinical validation. It raises product prices, making them less affordable for patients without comprehensive insurance coverage. Healthcare facilities in low-resource regions struggle to adopt these devices due to infrastructure gaps and budget constraints. Limited reimbursement policies further restrict patient access, creating disparities in treatment availability. These financial and structural barriers slow down the pace of global adoption.
Regulatory Complexities and Data Security Concerns Slowing Market Growth
The Neurotech Devices Market also encounters obstacles from stringent regulatory processes and data protection issues. Gaining approval for innovative neurotech products requires extensive clinical trials, which delay commercialization and increase costs. It creates uncertainty for companies attempting to bring breakthrough technologies to market quickly. At the same time, connected neurotech devices generate sensitive brain and health data, raising privacy and cybersecurity concerns. Patients and providers express caution about potential risks of data misuse or system breaches. Complex approval frameworks combined with security challenges create hurdles for faster adoption. These factors demand careful navigation by manufacturers and regulators.
Market Opportunities
Expanding Scope in Mental Health and Rehabilitation Creating Growth Potential
The Neurotech Devices Market holds strong opportunities through its widening role in mental health treatment and rehabilitation therapies. Rising cases of depression, anxiety, and post-traumatic stress disorder encourage the adoption of neuromodulation and brain-computer interface solutions. It supports healthcare providers in offering alternatives to traditional pharmaceuticals, improving treatment outcomes and patient satisfaction. Rehabilitation centers increasingly deploy neuroprosthetics and stimulation devices to restore mobility and functionality in patients recovering from strokes or spinal injuries. Growing acceptance of these technologies strengthens their presence across diverse clinical applications. This expansion unlocks new segments that contribute to sustained growth.
Integration with Digital Health Ecosystems Driving Future Adoption
The Neurotech Devices Market gains opportunities from the growing integration of neurotech solutions with digital health platforms and remote care models. Connected devices paired with mobile applications enable real-time monitoring, data sharing, and personalized treatment plans. It aligns with the global shift toward patient-centric care and home-based treatment. Partnerships between neurotech developers and telehealth providers enhance device accessibility and expand patient reach. Data-driven insights improve clinical decision-making, boosting confidence among physicians. This alignment with digital health ecosystems positions neurotech devices as a critical component of next-generation healthcare delivery.
Market Segmentation Analysis:
By Type
The Neurotech Devices Market segments into neurostimulation devices, neuroprosthetics, brain-computer interfaces, and monitoring devices. Neurostimulation devices dominate the market due to their extensive use in managing chronic pain, epilepsy, and movement disorders. It reflects strong clinical adoption supported by proven efficacy and expanding reimbursement coverage in developed regions. Neuroprosthetics gain momentum with rising demand for advanced mobility solutions and assistive technologies for patients with spinal cord injuries or limb loss. Brain-computer interfaces represent a rapidly growing segment, supported by increasing investment in research and applications across healthcare and defense. Monitoring devices continue to hold relevance in diagnostics, offering crucial support for early detection of neurological disorders.
For instance, Cochlear Limited reported fitting over 700,000 cochlear implants worldwide as of 2023, showcasing the significant adoption of neuroprosthetic solutions for hearing restoration.
By Condition
The Neurotech Devices Market addresses a wide range of neurological conditions including epilepsy, Parkinson’s disease, Alzheimer’s disease, depression, and chronic pain. Epilepsy remains a leading segment, supported by strong reliance on neurostimulation devices to reduce seizure frequency. Parkinson’s disease also drives significant adoption, with deep brain stimulation serving as a key therapy. It supports patients with mobility improvement and better management of motor symptoms. Mental health applications such as depression and anxiety represent a growing opportunity, driven by the rising global burden of psychiatric conditions. Chronic pain management continues to expand as patients seek non-pharmacological alternatives with long-term effectiveness.
For instance, Clinical studies, such as the INTREPID trial, have shown that Boston Scientific’s Vercise™ Deep Brain Stimulation (DBS) System significantly improves tremor and motor control outcomes for patients with advanced Parkinson’s disease. However, the claim that the Vercise system has been implanted in tens of thousands of only Parkinson’s disease patients is not substantiated. This is because Boston Scientific’s DBS systems are also approved for other conditions, such as essential tremor and dystonia. Furthermore, Boston Scientific does not publicly disclose figures for DBS implants broken down by condition or specific model.
By End-user
The Neurotech Devices Market segments by end-user into hospitals, specialty clinics, rehabilitation centers, and research institutions. Hospitals dominate the segment due to their access to advanced infrastructure, trained professionals, and wide patient base. Specialty clinics play a growing role in personalized neurological care, offering focused expertise and specialized device adoption. It strengthens the market by providing tailored treatment solutions outside large hospital systems. Rehabilitation centers emerge as critical end-users, particularly for neuroprosthetics and mobility-restoring technologies. Research institutions contribute significantly by advancing clinical studies, fostering innovation, and supporting commercialization of next-generation neurotech solutions. This diverse end-user base sustains broad market penetration and long-term growth.
Segments:
Based on Type
Neuroprosthetics
Neural stimulators
Neurorehabilitation
Neurosensing
Based on Condition
Pain Management
Parkinson’s Disease
Cerebral Palsy
Cognitive Disorders
Epilepsy
Incontinence
Migraine
Hearing Conditions
Chronic Pain
Spinal Cord Injury
Stroke Traumatic Brain Injury Others
Traumatic Brain Injury
Based on End-user
Hospitals
Ambulatory Surgical Center
Diagnostic Centers
Ambulatory Surgical Center
Home Care Facilities
Based on the Geography:
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Russia
Belgium
Netherlands
Austria
Sweden
Poland
Denmark
Switzerland
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Australia
Thailand
Indonesia
Vietnam
Malaysia
Philippines
Taiwan
Rest of Asia Pacific
Latin America
Brazil
Argentina
Peru
Chile
Colombia
Rest of Latin America
Middle East
UAE
KSA
Israel
Turkey
Iran
Rest of Middle East
Africa
Egypt
Nigeria
Algeria
Morocco
Rest of Africa
Regional Analysis
North America
North America holds the largest share of the Neurotech Devices Market, accounting for more than 40% of global revenue in 2024. The region benefits from advanced healthcare infrastructure, strong research and development activity, and high adoption of innovative medical technologies. It reflects a favorable reimbursement landscape that supports the use of neurostimulation devices, neuroprosthetics, and brain-computer interfaces. The United States leads with extensive clinical trials, active investment from venture capital firms, and strong collaboration between academia and industry. Canada also contributes to market strength through government-backed research programs and growing awareness of neurological health. The high prevalence of neurological disorders such as epilepsy, Parkinson’s disease, and chronic pain further drives demand, making North America the dominant regional contributor.
Europe
Europe represents the second-largest market, holding about 28% of global share in 2024. The region demonstrates consistent growth supported by robust healthcare systems, rising investments in neuroscience, and favorable regulatory frameworks. Germany, the United Kingdom, and France lead the regional adoption of neurotech devices, supported by high spending on healthcare technologies. It benefits from collaborative research initiatives funded by the European Union, which strengthen advancements in brain-computer interfaces and neuromodulation solutions. Patients across the region increasingly accept minimally invasive and wearable devices, driving adoption across hospitals and specialty clinics. Rising cases of neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease continue to create demand. Europe’s emphasis on early diagnosis and preventive care sustains steady growth in the neurotech sector.
Asia Pacific
Asia Pacific holds around 20% of global market share in 2024, and it is expected to register the fastest growth during the forecast period. The region benefits from expanding healthcare infrastructure, growing investment in medical technology, and increasing awareness of neurological health. China, Japan, and India lead the adoption of neurotech devices, supported by large patient populations and rising government healthcare spending. It also reflects strong opportunities for market expansion due to ongoing digital health adoption and growing acceptance of remote care solutions. Japan plays a key role in advancing brain-computer interface research, while China drives large-scale commercialization and local manufacturing. Rising cases of mental health conditions and neurological disorders across the region strengthen the demand outlook. Asia Pacific’s combination of strong population base and improving access to advanced healthcare ensures long-term potential.
Latin America
Latin America accounts for nearly 7% of global revenue in 2024, with Brazil and Mexico as the leading markets. The region shows growing adoption of neurotech devices due to improving healthcare investments and rising awareness of neurological conditions. It faces certain challenges related to limited reimbursement policies and uneven infrastructure, yet strong demand for chronic pain and epilepsy management supports growth. Hospitals and specialty clinics gradually expand the use of neurostimulation and neuroprosthetic solutions. Rising collaborations with North American and European companies help introduce advanced technologies to the region. Government initiatives aimed at strengthening healthcare accessibility create opportunities for wider adoption. Latin America’s expanding private healthcare sector enhances long-term growth prospects.
Middle East and Africa
The Middle East and Africa collectively hold around 5% of the global Neurotech Devices Market in 2024. The region shows gradual adoption, driven by increasing healthcare modernization efforts and growing interest in advanced neurological treatments. Gulf Cooperation Council (GCC) countries such as Saudi Arabia and the United Arab Emirates lead market development, supported by strong investments in healthcare infrastructure. It also reflects potential in South Africa, where rising neurological disease prevalence creates demand for advanced treatment solutions. Limited access to specialized care and high device costs remain challenges across several African nations. However, ongoing partnerships with international healthcare providers and technology firms support gradual adoption. The region’s focus on modernizing healthcare systems is expected to create steady growth opportunities over the forecast period.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Competitive landscape of the Neurotech Devices Market is defined by key players such as Medtronic plc, Boston Scientific Corporation, Cochlear Limited, LivaNova PLC, Nihon Kohden Corporation, Natus Medical Incorporated, Integra LifeSciences, BrainCo, Inc., Control Bionics, Inc., and Blackrock Microsystems. The market features a balanced mix of established medical technology leaders and emerging innovators, each contributing unique strengths that shape industry growth. Established players bring strong global distribution networks, extensive R&D investments, and a consistent track record of regulatory approvals, ensuring widespread clinical adoption of advanced neurotech devices. Market leaders focus on neurostimulation, implantable devices, hearing implants, and neuromodulation therapies that address major neurological conditions such as epilepsy, hearing loss, and movement disorders. Diagnostic and monitoring systems, neurodiagnostic tools, and rehabilitation devices further expand the product portfolio, strengthening clinical utility. On the other hand, smaller innovators emphasize brain-computer interfaces, assistive neurotechnologies, and research-driven advancements that target niche applications and create new opportunities for patient care. This blend of competition fuels continuous product development and rapid technological evolution across the sector. Strategic collaborations, partnerships with healthcare institutions, and global expansion strategies remain central to maintaining competitive advantage. The result is a dynamic, innovation-driven market that ensures a broad range of neurological healthcare solutions.
Recent Developments
In May 2025, Cognixion announced that Blackrock Neurotech would distribute its non-invasive Axon-R wearable neural interface platform to research institutions.
In February 2025, Medtronic plc, the U.S. FDA approved its adaptive deep brain stimulation (DBS) system for Parkinson’s disease— the first closed-loop DBS implant that adjusts stimulation based on neural activity.
In November 2024, Nihon Kohden Corporation, the company acquired a 71.4 % stake in NeuroAdvanced Corp., the parent of Ad-Tech Medical Instrument Corporation, enhancing its portfolio with specialized neural electrodes for epilepsy and diagnostic use.
In October 2024, BrainCo introduced OxyZen, a headband that monitors heart rate, blood oxygen, and brainwaves to enhance meditation and sleep.
Report Coverage
The research report offers an in-depth analysis based on Type, Condition, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Growing integration of artificial intelligence will drive smarter and more adaptive neurotech solutions.
Expanding use of wearable and home-based devices will increase patient convenience and long-term monitoring.
Wider adoption in mental health care will unlock new clinical applications beyond traditional neurological treatment.
Collaboration between tech firms and medical researchers will accelerate breakthrough innovations.
Growing interest in brain-computer interfaces will broaden applications in rehabilitation and human augmentation.
Rising demand for minimally invasive options will push manufacturers toward sleeker device designs.
Remote care platforms will integrate neurotech devices for seamless telemedicine delivery.
Government investments in neuroscience research will fuel public-private development initiatives.
Standardized regulatory pathways will shorten commercialization timelines and reduce market entry risks.
Enhanced data security protocols will build trust and support broader adoption across healthcare settings.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Global Neurotech Devices Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
12. Porters Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
13. Price Analysis
14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Nihon Kohden Corporation
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Medtronic plc
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. Financials
14.3.2.4. SWOT Analysis
14.3.3. Blackrock Microsystems
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. Financials
14.3.3.4. SWOT Analysis
14.3.4. LivaNova PLC
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. Financials
14.3.4.4. SWOT Analysis
14.3.5. Natus Medical Incorporated
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. Financials
14.3.5.4. SWOT Analysis
14.3.6. BrainCo, Inc
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. Financials
14.3.6.4. SWOT Analysis
14.3.7. Control Bionics, Inc
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. Financials
14.3.7.4. SWOT Analysis
14.3.8. Cochlear Limited
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. Financials
14.3.8.4. SWOT Analysis
14.3.9. Integra LifeSciences
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. Financials
14.3.9.4. SWOT Analysis
14.3.10. Boston Scientific Corporation
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. Financials
14.3.10.4. SWOT Analysis
15. Research Methodology
Request Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Neurotech Devices, and what is its projected size in 2032?
The Neurotech Devices market was valued at USD 14.5 billion in 2024 and is projected to reach USD 32.9 billion by 2032.
At what Compound Annual Growth Rate is the Neurotech Devices market projected to grow between 2025 and 2032?
The Neurotech Devices market is expected to grow at a CAGR of 10.8% from 2025 to 2032.
Which Neurotech Devices market segment held the largest share in 2024?
Neurostimulation devices held the largest share of the Neurotech Devices market in 2024, driven by strong adoption in managing chronic pain and epilepsy.
What are the primary factors fueling the growth of the Neurotech Devices market?
The Neurotech Devices market growth is fueled by rising neurological disorders, increasing demand for minimally invasive treatments, and advancements in brain-computer interfaces and neuroprosthetics.
Who are the leading companies in the Neurotech Devices market?
Key players in the Neurotech Devices market include Medtronic plc, Boston Scientific Corporation, Cochlear Limited, Nihon Kohden Corporation, and LivaNova PLC.
Which region commanded the largest share of the Neurotech Devices market in 2024?
North America commanded the largest share of the Neurotech Devices market in 2024, supported by advanced healthcare infrastructure and high adoption of innovative technologies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Second-Hand Fashion Market was valued at USD 190 billion in 2024 and is projected to reach USD 422.3 billion by 2032, expanding at a CAGR of 10.5% during the forecast period.
The Passenger Tire Market was valued at USD 156.1 billion in 2024 and is projected to reach USD 210.3 billion by 2032, expanding at a CAGR of 3.8% during the forecast period.
The Passenger Vehicles Market was valued at USD 1705.2 billion in 2024 and is anticipated to reach USD 2805.1 billion by 2032, growing at a CAGR of 6.42% during the forecast period.
Operator Training Simulator Market size was valued at USD 12.4 billion in 2024 and is anticipated to reach USD 35.7 billion by 2032, at a CAGR of 14.1% during the forecast period.
The UK Anesthesia Breathing Filters Market size was valued at USD 3.75 million in 2018 to USD 4.68 million in 2024 and is anticipated to reach USD 6.35 million by 2032, at a CAGR of 3.60% during the forecast period.
Secure Logistics Market size was valued at USD 88 billion in 2024 and is anticipated to reach USD 136.2 billion by 2032, at a CAGR of 5.62% during the forecast period.
The Zeolite Molecular Sieve Market size was valued at USD 4609.8 million in 2024 and is anticipated to reach USD 7744.6 million by 2032, at a CAGR of 6.7% during the forecast period (2024-2032).
The Non-Alcoholic Beer Market size was valued at USD 19 million in 2024 and is projected to reach USD 34.4 million by 2032, expanding at a CAGR of 7.7% during the forecast period.
The Non-Alcoholic RTD Beverages Market was valued at USD 760.6 million in 2024 and is anticipated to reach USD 1178 million by 2032, growing at a CAGR of 5.62% during the forecast period.
Purchase Options
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
